DEF 14A: Axogen Seeks Shareholder Approval for Incentive Plan Expansion Amid Leadership Transition

Axogen is asking shareholders to approve an increase in shares authorized for issuance under its long-term incentive plan to maintain competitive compensation during a period of significant leadership changes.

Summary

• Axogen is seeking shareholder approval to increase the number of shares authorized under its 2019 Long-Term Incentive Plan from 8,000,000 to 10,500,000.
• The request comes during a period of significant leadership transition, including the planned retirement of the CEO, departure of the CFO, and retirements of other executives.
• The company emphasizes the importance of equity-based compensation to retain key employees and attract new talent, especially during this transition.
• Revenue grew by 14.7% in 2023 compared to 2022, but stock price performance lagged.
• The Compensation Committee aims to align executive compensation with long-term stock price performance and near-term strategic regulatory objectives.
• Without additional shares, Axogen may need to limit equity participation or increase cash compensation to remain competitive.
• The proposed increase is considered vital for building a stable and incentivized leadership team and driving long-term value for shareholders.
• The company plans to focus on performance-based equity to drive results.

Sentiment

Score: 7

Explanation: The document expresses a moderately positive sentiment. While acknowledging leadership transitions and stock price underperformance, it emphasizes revenue growth, strategic initiatives, and the importance of retaining and attracting talent. The request for additional shares is presented as a necessary step to ensure future success.

Positives

• Revenue grew by 14.7% in 2023 compared to 2022.
• The company's growth strategy focuses on expanding its footprint in Core Accounts, which increased to 376 in 2023.
• Axogen launched Axoguard HA+ Nerve Protector in 2023, designed for shortand long-term nerve protection.
• The company completed construction and validation of a new processing facility to support its BLA for Avance Nerve Graft.
• For the 2023 annual cash incentive, a total of 109.1% of targeted bonus amounts were earned by named executive officers.
• The company received approximately 94% of votes in support of the say-on-pay proposal at the 2023 annual meeting.

Negatives

• The company's stock price performance lagged despite improved financial and strategic performance.
• The company announced significant leadership changes in the last six-month period.
• Shareholders did not approve an amendment to the A&R 2019 Plan at the last annual meeting.

Risks

• Failure to approve the share increase could limit equity participation and hinder the company's ability to retain and attract top talent.
• Inability to provide competitive equity grants could challenge the company's ability to build a stable and incentivized leadership team.
• The company's future success depends on the efforts and skills of its officers and other key employees and directors.

Future Outlook

The company plans to be even more targeted and focused on the use of performance-based equity to drive results.

Management Comments

• Although financial and strategic performance improved, for example we grew revenue in 2023 by 14.7% compared with 2022 and made significant progress toward readying our Biologic License Application (BLA) for Avance Nerve Graft, our stock price performance lagged.
• During our transition in leadership, and as we focus efforts to increase commercial performance, it is especially important to assure stability and retention of key employees by providing appropriate equity-based compensation that provides value only if we are successful.
• Going forward, as we did in early 2024, we plan to be even more targeted and focused on the use of performance-based equity to drive results and I will work together with the Compensation Committee of our Board of Directors to that end.

Industry Context

The document highlights the competitive landscape for talent in the medical device industry and the importance of equity compensation in attracting and retaining qualified executives.

Comparison to Industry Standards

• The document mentions using a peer group of HealthCare Equipment & Supplies companies to benchmark executive compensation.
• The peer group includes companies with market capitalization and revenue similar to Axogen, such as AngioDynamics, Paragon 28, and Silk Road Medical.
• The document also considers biotech/biopharma companies to broaden the market perspective.

Management Changes

Corporate Governance

Related Party Transactions

• The Company may make contributions to the Global Nerve Foundation (GNF), a related party, due to certain executives of the Company being members of GNF's board of directors.
• The Company's Board of Directors authorized the Company to enter into an agreement to contribute $0.8 million to GNF between 2023 and 2031, but no agreement has been executed between the Company and GNF.

Stakeholder Impact

• Approval of the share increase is intended to benefit shareholders by enabling the company to attract and retain key talent, driving long-term value.
• Employees are impacted by the potential changes to equity compensation and the company's ability to offer competitive packages.
• The company's performance and strategic initiatives ultimately impact patients and healthcare providers through the development and commercialization of nerve repair solutions.

Next Steps

• Shareholder vote on the approval of the Axogen, Inc. Third Amended and Restated 2019 Long-Term Incentive Plan.
• Implementation of the new processing facility for Avance Nerve Graft.
• Continued execution of the company's market development strategy.

Key Dates

Keywords

executive compensation, long-term incentive plan, equity grants, shareholder approval, leadership transition, retention, talent acquisition, performance-based equity, Axogen, compensation